A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

NCT01781442

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects that will be included in this post marketing surveillance study must be consistent with the approved label indication of Torisel in the Philippines.

- As per approved label indication, patients diagnosed with advanced renal cell carcinoma will be the ones eligible to participate in the study.

- The decision to prescribe Torisel will necessarily precede and will be independent of the decision to enroll the patient into the study.

- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects with conditions that are contraindicated with Torisel based on the approved
local product document in the Philippines will be excluded in this study. This
condition includes: Patients with bilirubin >1.5 x ULN.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Renal Cell CarcinomaAxitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer NCT00835978
  1. Antioch, California
  2. Bakersfield, California
  3. Pleasant Hill, California
  4. Pleasant Hill, California
  5. Pleasant Hill, California
  6. San Leandro, California
  7. Tampa, Florida
  8. Indianapolis, Indiana
  9. Indianapolis, Indiana
  10. Indianapolis, Indiana
  11. Baltimore, Maryland
  12. Baltimore, Maryland
  13. Baltimore, Maryland
  14. Boston, Massachusetts
  15. Boston, Massachusetts
  16. Grand Rapids, Michigan
  17. Saint Louis, Missouri
  18. Saint Louis, Missouri
  19. Omaha, Nebraska
  20. Omaha, Nebraska
  21. Las Vegas, Nevada
  22. Cincinnati, Ohio
  23. Cincinnati, Ohio
  24. Cleveland, Ohio
  25. Columbus, Ohio
  26. Columbus, Ohio
  27. West Chester, Ohio
  28. Portland, Oregon
  29. Dallas, Texas
  30. Houston, Texas
  31. Seattle, Washington
  32. Brno, CZE
  33. Olomouc,
  34. Praha 8,
  35. Usti nad Labem,
  36. Duesseldorf,
  37. Frankfurt,
  38. Hannover,
  39. Tuebingen,
  40. Weiden,
  41. Nagoya, Aichi
  42. Sapporo, Hokkaido
  43. Sapporo, Hokkaido
  44. Kobe, Hyogo
  45. Osakasayama, Osaka
  46. Hamamatsu-City, Shizuoka
  47. Chuo-ku, Tokyo
  48. Koto-ku, Tokyo
  49. Shinjuku-ku, Tokyo
  50. Akita,
  51. Chiba,
  52. Fukuoka,
  53. Nagasaki,
  54. Tokushima,
  55. Yamagata,
  56. Obninsk, Kaluga Region
  57. Poselok Kuzmolovskiy, Vsevolozhskiy Region, Leningradskaya Oblast
  58. Moscow,
  59. Moscow,
  60. Saint-Petersburg,
  61. Saint-Petersburg,
  62. Samara,
  63. Madrid,
  64. Madrid,
  65. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaTreatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma NCT00130897
  1. Scottsdale, Arizona
  2. San Francisco, California
  3. San Francisco, California
  4. Aurora, Colorado
  5. Norwalk, Connecticut
  6. Miami, Florida
  7. Ocala, Florida
  8. Tampa, Florida
  9. Atlanta, Georgia
  10. Maywood, Illinois
  11. Indianapolis, Indiana
  12. Council Bluffs, Iowa
  13. Covington, Louisiana
  14. Gretna, Louisiana
  15. Marrero, Louisiana
  16. Metairie, Louisiana
  17. Metairie, Louisiana
  18. New Orleans, Louisiana
  19. Baltimore, Maryland
  20. Boston, Massachusetts
  21. Boston, Massachusetts
  22. Boston, Massachusetts
  23. Detroit, Michigan
  24. Minneapolis, Minnesota
  25. Southaven, Mississippi
  26. Tupelo, Mississippi
  27. Columbia, Missouri
  28. Columbia, Missouri
  29. Omaha, Nebraska
  30. Bronx, New York
  31. New York, New York
  32. New York, New York
  33. Durham, North Carolina
  34. Cleveland, Ohio
  35. Norman, Oklahoma
  36. Oklahoma City, Oklahoma
  37. Oklahoma City, Oklahoma
  38. Oklahoma City, Oklahoma
  39. Oklahoma City, Oklahoma
  40. Tulsa, Oklahoma
  41. Tulsa, Oklahoma
  42. Portland, Oregon
  43. Portland, Oregon
  44. Hershey, Pennsylvania
  45. Memphis, Tennessee
  46. Memphis, Tennessee
  47. Dallas, Texas
  48. Salt Lake City, Utah
  49. Seattle, Washington
  50. Seattle, Washington
  51. Seattle, Washington
  52. Seattle, Washington
  53. Madison, Wisconsin
  54. Buenos Aires,
  55. Buenos Aires,
  56. Buenos Aires,
  57. Randwick, New South Wales
  58. St Leonards, New South Wales
  59. Westmead, New South Wales
  60. South Brisbane, Queensland
  61. Elizabeth Vale, South Australia
  62. Woodville South, South Australia
  63. East Melbourne, Victoria
  64. Heidelburg, Victoria
  65. Perth, Western Australia
  66. Innsbruck,
  67. Wien,
  68. Bruxelles,
  69. Bruxelles,
  70. Gent,
  71. Leuven,
  72. Liege,
  73. Wilrijk,
  74. Sarajevo,
  75. Salvador, BA
  76. Belo Horizonte, MG
  77. Porto Alegre, Rio Grande do Sul
  78. Rio de Janeiro, RJ
  79. Rio de Janeiro, RJ
  80. Porto Alegre, RS
  81. Jau, SP
  82. Jaú, SP
  83. Jaú, SP
  84. São Paulo, SP
  85. São Paulo, SP
  86. São Paulo, SP
  87. Sofia,
  88. Sofia,
  89. Calgary, Alberta
  90. Edmonton, Alberta
  91. Kelowna, British Columbia
  92. Vancouver, British Columbia
  93. Victoria, British Columbia
  94. Winnipeg, Manitoba
  95. Winnnipeg, Manitoba
  96. St. John's, Newfoundland and Labrador
  97. Halifax, Nova Scotia
  98. Halifax, Nova Scotia
  99. London, Ontario
  100. Toronto, Ontario
  101. Toronto, Ontario
  102. Montreal, Quebec
  103. Montreal, Quebec
  104. Quebec,
  105. Santiago, RM
  106. Bogotá, Cundinamarca
  107. Cali,
  108. Rijeka,
  109. Split,
  110. Brno,
  111. Hradec Kralove,
  112. Praha 5,
  113. Praha 8,
  114. Guayaquil, Guayas
  115. Quito, Pichincha
  116. Cairo,
  117. Giza,
  118. Turku,
  119. Lyon, Cedex 08
  120. Saint Herblain, Cedex
  121. Strasbourg, Cedex
  122. Bordeaux,
  123. Clermont Ferand,
  124. Marseille Cedex 9,
  125. Marseille,
  126. Montpellier,
  127. Paris Cedex 13,
  128. Paris,
  129. Reims,
  130. Rennes,
  131. Tours,
  132. Vandoeuvre les Nancy,
  133. Aachen,
  134. Berlin,
  135. Dresden,
  136. Essen,
  137. Frankfurt,
  138. Freiburg,
  139. Hamburg,
  140. Hannover,
  141. Homburg/Saar,
  142. Jena,
  143. Kassel,
  144. Muenchen,
  145. Nuernberg,
  146. Rostock,
  147. Ulm,
  148. Athens, Attiki
  149. Athens,
  150. Patras,
  151. Thessaloniki,
  152. Hong Hong,
  153. Budapest,
  154. New Delhi, Delhi
  155. Pune, Maharashtra
  156. Parel, Mumbai
  157. Jaipur, Rajasthan
  158. New Delhi,
  159. Dublin 24,
  160. Dublin,
  161. Jerusalem,
  162. Tel Hashomer,
  163. Bergamo,
  164. Brescia,
  165. Cattolica (RN),
  166. Cuneo,
  167. Legnago, VR,
  168. Modena,
  169. Napoli,
  170. Padova,
  171. Parma,
  172. Pavia,
  173. Perugia,
  174. Pordenone,
  175. Rimini,
  176. Roma,
  177. Roma,
  178. Roma,
  179. Torino,
  180. Seoul,
  181. Seoul,
  182. Beirut,
  183. Petaling Jaya, Selangor
  184. Kuala Lumpur,
  185. Mexico, DF
  186. Mexico, DF
  187. Toluca, Estado de Mexico
  188. Guadalajara, Jalisco
  189. Merida, Yucatan
  190. Chihuahua,
  191. Puebla,
  192. Groningen, GR
  193. Amsterdam, NH
  194. Amsterdam,
  195. Rotterdam,
  196. Oslo,
  197. Ciudad de Panama,
  198. Panama,
  199. Lima,
  200. Lima,
  201. Quezon City,
  202. Quezon City,
  203. Gdansk,
  204. Lodz,
  205. Poznan,
  206. Warszawa,
  207. Wroclaw,
  208. Lisboa,
  209. Porto,
  210. Bucuresti,
  211. Cluj-Napoca,
  212. Obninsk, Kaluga region
  213. Chelyabinsk,
  214. Moscow,
  215. Belgrade,
  216. Singapore,
  217. Bratislava,
  218. Zilina,
  219. Ljubljana,
  220. Oviedo, Asturias
  221. L'hospitalet Del Llobregat, Barcelona
  222. Pamplona, Navarra
  223. Baracaldo, Vizcaya
  224. Barcelona,
  225. Barcelona,
  226. La Coruña,
  227. Madrid,
  228. Madrid,
  229. Madrid,
  230. Salamanca,
  231. Sevilla,
  232. Valencia,
  233. Göteborg,
  234. Lund,
  235. Stockholm,
  236. Umeå,
  237. Basel,
  238. Bellinzona,
  239. Bern,
  240. Biel,
  241. CH-4058 Basel,
  242. CH-4101 Bruderholz,
  243. CH-4410 Liesthal,
  244. Chur,
  245. Genève 14,
  246. Taipei,
  247. Taipei,
  248. Taoyun,
  249. Bangkok,
  250. Bangkok,
  251. Istanbul, Capa
  252. Istanbul, Cerrahpasa
  253. Whitchurch, Cardiff
  254. London, Se1 9rt
  255. Sutton, Surrey
  256. Leeds, West Yorkshire
  257. Belfast,
  258. Birmingham,
  259. Birmingham,
  260. Bristol,
  261. Cottingham,
  262. Edinburgh,
  263. Guildford,
  264. London,
  265. London,
  266. London,
  267. Manchester,
  268. Northwood,
  269. Nottingham,
  270. Sheffield,
  271. Southampton,
  272. Swansea,
  273. Caracas, Distrito Capital
  274. Caracas, Estado Miranda
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Renal Cell CarcinomaSUTENT® In The First Line Treatment Of Renal Cell Carcinoma NCT00460798
ALL GENDERS
0+
years
MULTIPLE SITES
Renal Cell CarcinomaA Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. NCT00077974
  1. Duarte, California
  2. Pasadena, California
  3. San Francisco, California
  4. Boston, Massachusetts
  5. Boston, Massachusetts
  6. Boston, Massachusetts
  7. Ann Arbor, Michigan
  8. Rochester, Minnesota
  9. New York, New York
  10. New York, New York
  11. Durham, North Carolina
  12. Cleveland, Ohio
  13. Portland, Oregon
  14. Philadelphia, Pennsylvania
  15. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
Official Title An Open Label, Non-interventional Study Of The Safety Of Temsirolimus Injection (Torisel) In The Treatment Of Advanced Renal Cell Carcinoma In Filipino Adult Patients: A Post Marketing Surveillance Study
Brief Summary This is a post marketing surveillance which determines the safety profile of the product to Filipinos. This is a FDA requirement for registration.
Detailed Description

The Philippine Food and Drug Administration requires that a post marketing surveillance study be conducted nationwide and enroll approximately 3,000 study patients. In cases where the 3,000 patients will not be met, the total sample size can be reduced to 10% of the volume of drug use during the first year of it being marketed. Final sample size will be determined after one year of marketing authorization. The decision to use Torisel must be a joint decision made by the subject and the investigator.

The investigator must discuss product information with the subject as per usual practice.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population This is a prospective observational, non-interventional study which will evaluate Torisel in Filipino adult subjects. Because the data to be collected will be under routine clinical conditions, subjects who have any of the contraindications specified in the product package insert are to be excluded. Torisel will be prescribed and administered according to the approved product information of the drug in the Philippines. Pfizer will not provide the drug for this study.
Condition Renal Cell Carcinoma
Intervention Drug: Temsirolimus

The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.

Treatment will continue until disease progression or unacceptable toxicity.

The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity.

Study Groups/Cohorts Patient Arm- temsirolimus
Intervention: Drug: Temsirolimus
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: April 30, 2013)
0
Original Estimated Enrollment
 (submitted: January 30, 2013)
20
Estimated Study Completion Date June 2015
Estimated Primary Completion Date June 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Subjects that will be included in this post marketing surveillance study must be consistent with the approved label indication of Torisel in the Philippines.
  • As per approved label indication, patients diagnosed with advanced renal cell carcinoma will be the ones eligible to participate in the study.
  • The decision to prescribe Torisel will necessarily precede and will be independent of the decision to enroll the patient into the study.
  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

  • Subjects with conditions that are contraindicated with Torisel based on the approved local product document in the Philippines will be excluded in this study. This condition includes: Patients with bilirubin >1.5 x ULN.
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01781442
Other Study ID Numbers B1771110
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2013